Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 23.18 USD -0.94%
Market Cap: 163.4m USD
Have any thoughts about
Cidara Therapeutics Inc?
Write Note

Cidara Therapeutics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cidara Therapeutics Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Cidara Therapeutics Inc
NASDAQ:CDTX
Total Current Liabilities
$44.3m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
46%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Cidara Therapeutics Inc
Glance View

Market Cap
163.3m USD
Industry
Biotechnology

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

CDTX Intrinsic Value
9.28 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cidara Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
44.3m USD

Based on the financial report for Sep 30, 2024, Cidara Therapeutics Inc's Total Current Liabilities amounts to 44.3m USD.

What is Cidara Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
46%

Over the last year, the Total Current Liabilities growth was 24%. The average annual Total Current Liabilities growth rates for Cidara Therapeutics Inc have been 10% over the past three years , 7% over the past five years , and 46% over the past ten years .

Back to Top